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Abstract
Recombinant vectors based on adeno-associated virus serotype 8 (AAV8) have been successfully used in the clinic
and hold great promise for liver-directed gene therapy. Preexisting immunity against AAV8 or the development of
antibodies against the therapeutic transgene product might negatively affect the outcomes of gene therapy. In the
prospect of an AAV8-mediated, liver-directed gene therapy clinical trial for mucopolysaccharidosis VI (MPS VI), a
lysosomal storage disorder caused by arylsulfatase B (ARSB) deficiency, we investigated in a multiethnic cohort of
MPS VI patients the prevalence of neutralizing antibodies (Nab) to AAV8 and the presence of ARSB cross-reactive
immunologic material (CRIM), which will either affect the efficacy of gene transfer or the duration of phenotypic
correction. Thirty-six MPS VI subjects included in the study harbored 45 (62.5%) missense, 13 (18%) nonsense, 9
(12.5%) frameshift (2 insertions and 7 deletions), and 5 (7%) splicing ARSB mutations. The detection of ARSB
protein in 24 patients out of 34 (71%) was predicted by the type of mutations. Preexisting Nab to AAV8 were
undetectable in 19/33 (58%) analyzed patients. Twelve out of 31 patients (39%) tested were both negative for Nab
to AAV8 and CRIM-positive. In conclusion, this study allows estimating the number of MPS VI patients eligible
for a gene therapy trial by intravenous injections of AAV8.
Introduction
Mucopolysaccharidosis VI (MPS VI) or Maroteaux–Lamy syndrome is an autosomal recessive disorder
caused by deficiency of the enzyme arylsulfatase B (ARSB),
which results in lysosomal storage of the glycosaminoglycan
(GAG) dermatan sulfate (DS). Clinical features of the disease
include growth retardation, skeletal dysplasia, joint stiffness,
organomegaly, heart valve disease, and corneal clouding
without primary involvement of the central nervous system.1
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Enzyme replacement therapy (ERT) is currently the stan-
dard of care for MPS VI.2 However, despite amelioration of
both visceral phenotype and endurance, ERT has limited ef-
ficacy on several MPS VI complications such as ocular, car-
diac, and skeletal abnormalities. In addition, ERT requires
inconvenient weekly infusions of costly recombinant en-
zyme2,3 that are associated with increased risks of adverse
reactions such as hypersensitivity reactions.4 Alternative
strategies with similar or better therapeutic efficacy without
the inconvenience and risks ofmultiple infusions are desirable.
We have recently demonstrated that a single intravenous
administration of a recombinant vector based on adeno-
associated virus serotype 8 (AAV2/8), which efficiently trans-
duces liver,5–8 results in long-term therapeutic efficacy in
rodent and feline models of MPS VI.9–13 Levels of serum
ARSB activity falling within the normal range were detected
in MPS VI cats up to 6 years postinjection, which was the last
time-point of observation (Ferla and Auricchio, unpublished
results). Based on these promising results, translation from
bench to bedside of this therapeutic strategy is now ongoing.
The outcome of in vivo gene transfer may be influenced
by several factors. Preexisting neutralizing antibodies (Nab)
to wild-type AAV8 even at low titers are sufficient to pre-
vent liver transduction by AAV2/8 vectors, and thus sig-
nificantly reduce the efficacy of gene therapy,14–17 as shown
also in MPS VI cats.11 Gene therapy efficacy may also be
limited by the development of humoral immunity to the
therapeutic transgene product. The immune response is
more likely to occur in patients or animal models that carry
bi-allelic null mutations in the disease-causative gene be-
cause of lack of cross-reactive immunologic material
(CRIM). Liver-directed gene transfer with either AAV or
lentiviral vectors has been shown to either prevent18 or
eradicate19,20 humoral immunity to the transgene product.
However, immune tolerization was not observed in MPS VI
rats that are homozygous for a null ARSB mutation.9,13
In the prospect of determining patients’ eligibility for a
clinical trial for MPS VI involving intravenous administra-
tions of AAV2/8 vectors, a multiethnic unselected cohort of
MPS VI patients from multiple metabolic clinics has been
evaluated for the presence of both Nab to AAV8 and CRIM
that will dictate eligibility and will likely affect the out-
comes of the clinical trial.
Patients, Materials, and Methods
Patients
The participants in the study were all MPS VI patients
diagnosed and followed-up at multiple metabolic clinics in
Italy (Catania, Florence, Naples, Monza, and Padua), in the
Netherlands (Rotterdam), and in Turkey (Ankara). The
clinical research protocol was approved by the Institutional
Review Board (IRB) of each participating metabolic clinic.
All patients signed an informed consent to be included in the
study. The study included the following assessments: (1)
clinical and instrumental (height or length; endurance
through the 6min walk test and 3min stair climb; forced
vital capacity; forced expiratory volume at 1 min; joint
stiffness and pain, grip, and pinch scores; Childhood Health
Assessment Questionnaire scores; visual acuity and ocular
abnormalities by full ocular examination; and magnetic
resonance imaging of hand, wrist, and knee joints performed
in cooperative subjects); (2) biochemical (urinary GAGs,
ARSB levels in serum, leucocytes and/or fibroblasts, dosage
of Nab to AAV8, clinical chemistry and hematology, and
HBV and HCV tests); and (3) molecular (DNA sequencing
of the ARSB gene; see below for details).
The molecular and clinical findings of these patients are
summarized in Tables 1 and 2. The involvement of the main
tissue/organs affected by the disease at the age of last
evaluation was graded by the referring clinicians as absent
(0), mild (1), moderate (2), or severe (3). A disease severity
score ranging from 0 (least severe) to 21 (most severe) was
assigned based on the degree of severity of each affected
tissue/organ (n = 7 tissues/organs).
Cell culture
Cultured skin fibroblasts from MPS VI patients obtained
for diagnostic purposes were maintained in Dulbecco’s
modified Eagle’s medium (Gibco–Life Invitrogen, Paisley,
UK) containing 20% fetal bovine serum (Gibco, Invitrogen
Corporation, Carlsbad, CA), 1% of Glutamine (Sigma-
Aldrich, Steinheim, Germany), and 1% antibiotic–antimycotic
(Gibco, Invitrogen Corporation).
Mutational analysis of the ARSB gene
Genomic DNA was extracted from cultured skin fibroblasts
by phenol/chloroform extraction. All ARSB exons were am-
plified by PCR, using M13-tailed primers. Sanger sequencing
was performed with an ABI PRISM 3130 XL automatic DNA
Sequencer Genetic Analyzer (Applied Biosystems, Foster
City, CA). Primer sequences and PCR conditions are described
in Supplementary Table S1 (Supplementary Data are available
online at www.liebertpub.com/hum).
ARSB cross-reactive immunologic material analysis
The presence of ARSB cross-reactive immunologic mate-
rial was evaluated by Western blot analysis of cultured skin
fibroblast lysates. Cells were lysed in RIPA buffer (50mM
NaCl, 25mM Tris-HCl pH 8.0, 0.5% NP40, 0.1% SDS, and
10mg/ml leupeptin–aprotinin–pepstatin A). Seventy micro-
grams of proteins were separated by SDS-PAGE on a 10%
polyacrylamide gel, transferred to a polyvinylidene difluoride
membrane (Roche, Basel, Switzerland), and incubated with
the following antibodies: (1) sheep polyclonal anti-ARSB
antibody, diluted to 1:500 in 5% milk, prepared as previously
described,21 and (2) mouse monoclonal anti-beta actin anti-
body (A5441; Sigma-Aldrich, Milan, Italy), diluted to 1:3000
in 5% nonfat dried milk (Euroclone, Milan, Italy).
Nab to AAV assay
MPS VI patients were screened for preexisting Nab to
AAV8 using an in vitro transduction inhibition assay with
Huh7 cells, as previously described.22 The detection limit of
the assay is a 1:5 serum dilution.
Results
ARSB mutations and ARSB cross-reactive
immunologic material in MPS VI patients
Serum and skin fibroblasts from 36 patients with a clinical
diagnosis of MPS VI confirmed by ARSB deficiency on
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enzyme assay were collected from referral metabolic clinic
centers in Italy, the Netherlands, and Turkey, which provided
samples from 7, 11, and 18 MPS VI patients, respectively
(Tables 1 and 2). The age of patients ranged from 5 to 25
years (age 5–10, n= 15; age 11–18, n= 18; age 19–25, n= 3;
Table 1) and their severity varied significantly (Table 2).
At the time of this study, molecular diagnoses of MPS VI
were already available for 18 out of the 36 patients.23–25 In the
remaining 18 patients, PCR amplification and Sanger se-
quencing of all ARSB exons and intron–exon boundaries were
carried out. Collectively, we observed 45/72 (62.5%) mis-
sense, 13/72 (18%) nonsense, 9/72 (12.5%) frameshift (2 in-
sertions and 7 deletions), and 5/72 (7%) splicing ARSB
mutations (Table 1). To the best of our knowledge, three
mutations had not been previously described. These were one
missense (c.1178A>G p.H393R), not reported in dbSNP or in
exome server databases, resulting in the change of a highly
conserved histidine residue (Supplementary Fig. S1) that had
already been found to be mutated in MPS VI,26 and two
frameshift mutations (883-884duplTT [p.F295FfsX42],
c.1036delG [p.E346SfsX11], Table 1) predicted to result in
truncated proteins.
Genotypes of MPS VI patients were correlated with the
presence of ARSB CRIM by Western blot analysis with
anti-ARSB antibody of lysates from cultured skin fibroblasts
(Fig. 1). In 24/34 (71%) of analyzed patients, 43 and 57 kDa
bands corresponding to ARSB mature and precursor pro-
teins, respectively, were detected (Fig. 1). Based on this
observation, these MPS VI patients were deemed CRIM
positive. Importantly, the CRIM status could be predicted
based on ARSB mutations; all patients bearing missense
mutations were consistently found to be CRIM positive,
whereas patients bearing null mutations in both alleles were
CRIM negative (Tables 1 and 2). No correlation between
clinical severity and CRIM status was observed (Fisher
exact test p-value = 0.2). However, the power of the test was
low (0.03) because of the small sample size, and thus de-
finitive conclusions on this aspect cannot be drawn.








1 Turkish c.962T >C/p.L321P c.962T >C/p.L321P Isbrandt et al.41
2 Turkish c.908G >A/p.G303E c.908G >A/p.G303E Lin et al.42
3 Turkish c.962T >C/p.L321P c.962T >C/p.L321P Isbrandt et al.41
4 Guinean c.971G >T/p.G324V c.971G >T/p.G324V Karageorgos et al.37
5 Turkish c.962T >C/p.L321P c.962T >C/p.L321P Isbrandt et al.41






8 Turkish c.903C >G/p.N301K c.903C >G/p.N301K Brands et al.23
9 Azerbaijan c.1036delG/p.E346SfsX11 c.1178A >G/p.H393R Novel
10 Turkish c.962T >C/p.L321P c.962T >C/p.L321P Isbrandt et al.41
11 Turkish c.571C >T/p.R191X c.571C >T/p.R191X Karageorgos et al.37
12 Italian del exon 5 del exon 5 a
13 Moroccan c.995T >G/p.V332G c.995T >G/p.V332G Brands et al.23
14 Turkish c.962T >C/p.L321P c.962T >C/p.L321P Isbrandt et al.41
15 Turkish c.962T >C/p.L321P c.962T >C/p.L321P Isbrandt et al.41
16 Turkish c.962T >C/p.L321P c.962T >C/p.L321P Isbrandt et al.41
17 Turkish c.571C >T/p.R191X c.571C >T/p.R191X Karageorgos et al.37
18 Turkish c.571C >T/p.R191X c.571C >T/p.R191X Karageorgos et al.37
19 Turkish c.962T >C/p.L321P c.962T >C/p.L321P Isbrandt et al.41
20 Venezuelan c.979C >T/p.R327X c.979C >T/p.R327X Karageorgos et al.43
21 Dutch c.629A >G/p.Y210C c.979C >T/p.R327X Litjens et al.26 and Karageorgos et al.43
22 Italian c.943C >T/p.R315X c.1475delC/pP492LfsX80 Voskoboeva et al.44 Di Natale et al.
23 Italian c.943C >T/p.R315X c.899-1142del Arlt et al.45 and Voskoboeva et al.44
24 Turkish c.962T >C/p.L321P c.962T >C/p.L321P Isbrandt et al.41
25 Dutch c.629A >G/p.Y210C c.979C >T/p.R327X Litjens et al.26 and Karageorgos et al.43
26 Dutch c.629A >G/p.Y210C c.979C >T/p.R327X Litjens et al.26 and Karageorgos et al.43
27 Pakistani c.1142 + 2T >C c.1142 + 2T>C Brands et al.23
28 Turkish c.454C >T/p.R152W c.454C >T/p.R152W Voskoboeva et al.46
29 Turkish c.454C >T/p.R152W c.454C >T/p.R152W Voskoboeva et al.46
30 Dutch c.629A >G/p.Y210C c.937C >G/p.P313A Litjens et al.26 and Brooks et al.47
31 Italian c.1213 + 6T >C c.725A >C/p.H242P Di Natale et al.24
32 Turkish c.1168G >A/p.E390K c.1168G >A/p.E390K Kantaputra et al.48
33 Turkish c.1036delG/p.E346SfsX11 c.1036delG/p.E346SfsX11 Novel
34 Italian c.1213 + 6T >C c.1213 + 6T>C Di Natale et al.24
35 Turkish c.454C >T/p.R152W c.454C >T/p.R152W Voskoboeva et al.46
36 Turkish c.1168G >A/p.E390K c.1168G >A/p.E390K Kantaputra et al.48
aPatient 12 (BA1196) carries a genomic deletion of exon 5 on both arylsulfatase B (ARSB) alleles; the breakpoints of the deletion were
not defined at the nucleotide levels.
NAB TO AAV8 AND ARSB CRIM IN MPS VI PATIENTS 147
Evaluation of Nab to AAV8 in MPS VI patients
Sera from MPS VI patients were analyzed using an
in vitro AAV2/8 transduction inhibition assay22 to detect
Nab to AAV8. Nab to AAV8 were undetectable in the sera
of 19/33 of analyzed patients (58%), whereas sera from the
remaining 14 patients (42%) showed a titer of Nab ‡ 1:5,
which is the detection limit of the assay (Table 2). The
seroprevalence was 31%, 47%, and 67% in patients whose
age ranged between 5 and 10, 11 and 18, and 19 and 25
years, respectively (Fig. 2a and b). The highest sero-
prevalence (67%) was found in patients from the referral
center in Turkey, followed by patients from the Dutch
(27%) and Italian (14%) referral centers (Fig. 2c). Statistical
analysis (Fisher exact test) suggested no association be-
tween Nab and age ( p= 0.5), and, conversely, a significant
difference between Nab and referral centers ( p = 0.05).
However, the power of the test was low (0.2 and 0.5, re-
spectively) because of the small sample size. Hence, de-
finitive conclusions on these aspects cannot be inferred.
Discussion
Gene therapy is emerging as a successful strategy for
treatment of inherited diseases.27 In vivo gene transfer with
AAV2/8 vectors is regarded as a possible approach to convert
the liver into a factory organ for systemic release of thera-
peutic proteins. A recent clinical trial using intravenous ad-
ministrations of AAV2/8 in patients with hemophilia B has
supported this paradigm in humans; some treated patients
exhibited multiyear stable factor IX levels following a single
administration of vector.15,28 By a similar approach, we have
recently demonstrated that a single systemic administration of
AAV2/8 encoding ARSB is able to convert the liver into a
Table 2. Clinical Severity, Cross-Reactive Immunologic Material Status, and Anti–Adeno-Associated























1 5/M 1.0 1.0 2 0 2 0 2 0 2 8 + n.a.
2 5/M 1.0 2.0 1 0 2 1 2 0 2 8 + < 5
3 5/F 4.0 4.0 1 2 2 1 1 0 1 8 n.a < 5
4 6/M 1.9 2.3 2 1 1 1 2 0 1 8 + 160
5 7/M 2.5 3.0 1 1 1 2 2 0 2 9 + 5
6 7/F 4.0 4.0 1 2 3 2 2 0 2 12 + 40
7 7/M 1.7 2.5 1 2 2 1 1 0 1 8 - < 5
8 7/F 1.8 2.1 2 1 2 3 2 0 2 12 + < 5
9 8/F 4.5 n.a 1 2 2 2 1 0 2 10 + n.a
10 8/M 3.0 3.0 1 2 2 2 1 0 1 9 + < 5
11 8/M 2.0 4.0 2 2 2 2 2 0 2 12 - 10
12 8/M 0.6 2.0 1 3 1 3 3 2 2 15 - < 5
13 9/F 2.8 2.9 2 0 2 2 2 1 2 11 + < 5
14 10/F 2.0 3.5 2 1 2 2 3 3 2 15 + < 5
15 10/M 1.0 4.0 2 1 2 2 3 2 2 14 + < 5
16 12/M 2.0 5.0 3 1 2 2 2 0 2 12 + 10
17 12/M 7.5 7.5 2 2 2 2 2 0 2 12 - 20
18 12/M 8.0 8.0 2 1 2 2 3 0 2 12 - 20
19 12/F 5.0 6.0 2 1 2 2 1 0 2 10 + n.a
20 12/M 5.0 5.4 2 2 1 3 3 3 3 17 - < 5
21 12/M 5.8 6.1 1 0 0 0 2 0 2 5 + 20
22 12/M 1.2 6.1 2 2 2 3 3 3 3 18 n.a < 5
23 12/M 1.6 4.0 2 2 2 2 2 1 2 13 - < 5
24 13/F 4.0 7.0 3 2 2 2 1 2 2 14 + 5
25 13/M 5.1 5.9 0 0 1 2 2 0 3 8 + < 5
26 13/F 7.4 7.8 0 0 0 2 2 0 2 6 + 640
27 13.5/F 3.4 6.8 2 2 3 3 3 0 3 16 - < 5
28 14/F 7.8 8.3 1 1 1 2 2 0 1 8 + < 5
29 14/M 0.7 7.6 0 0 1 0 2 0 2 5 + < 5
30 14/M 10.2 10.6 0 0 1 1 2 0 3 7 + < 5
31 14/F 4.0 6.0 1 0 1 1 1 1 0 5 + < 5
32 17/M 12 13.0 0 1 2 2 3 3 2 13 + 20
33 17/M 3.5 11.5 2 3 2 2 3 2 2 16 - 160
34 21/F 4.5 10.0 2 2 3 3 3 1 2 16 - 320
35 23/M 10.1 18.3 0 1 1 2 2 0 3 9 + < 5
36 25/F 23 24 0 1 2 2 3 2 2 12 + 20
CRIM, cross-reactive ARSB immunologic material; ENT, ear, nose, and throat; ERT, enzyme replacement therapy; F, female; M, male;
n.a, not available.
Involvement was graded as absent (0), mild (1), moderate (2), or severe (3).
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FIG. 1. ARSB CRIM in MPS VI patients. The presence of ARSB CRIM was evaluated by Western blot analysis of lysates
of cultured skin fibroblasts, as described in the Patients, Materials, and Methods section. Samples corresponding to each
ARSB genotype have been loaded in (a–c). Bands of 43 and 57 kDa corresponding to ARSB mature and precursor proteins,
respectively, are indicated by the arrows. ARSB, arylsulfatase B; CRIM, cross-reactive immunologic material; MPS,
mucopolysaccharidosis; NR CTR, normal control. The following mutations have not been described before: c.1178A >G
(p.H393R), 883-884duplTT (p.F295FfsX42), and c.1036delG (p.E346SfsX11).
FIG. 2. Seroprevalence of
Nab to AAV8 by age and
referral centers. The Nab titer
of each patient is reported in
(a). Data relative to Nab to
AAV8 in MPS VI patients
were additionally stratified
by age (b) and referral center
(c). The percentage of sam-
ples positive (Nab + , black
bar) and negative (Nab - ,
gray bar) for Nab to AAV8 is
reported in (b) and (c), and
the corresponding values are
inside each bar. The number
(n) of patients in each group
is indicated under each bar.
AAV8, adeno-associated vi-
rus serotype 8; Nab, neutral-
izing antibodies.
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factory organ, providing stable secretion of ARSB. This re-
sults in long-term therapeutic efficacy in rodent and feline
models of MPS VI.9–13 Gene therapy was at least as effective
as weekly infusions of recombinant human ARSB (rhARSB)
in a mouse model of MPS VI,12 suggesting that it may be
preferable to ERT, especially because it potentially requires a
single intravenous administration. This bodes well for further
investigating the safety and efficacy of intravenous adminis-
trations of AAV2/8 in patients with MPS VI.
Immune responses to the vector have been shown to limit
both efficacy and longevity of gene transfer.27,29 Very low
levels of Nab to AAV8 are sufficient to strongly reduce liver
transduction and thus therapeutic efficacy.11,14,16,17 Decoy
capsids that inhibit circulating Nab without interfering with
endogenous AAV receptors and AAV preparations with
empty capsids are two potential strategies to overcome the
barrier of preexisting anti-AAV antibodies.30 However, until
these strategies are demonstrated to be safe and efficient in
humans, the presence of circulating Nab to AAV8 is better
considered an exclusion criterion in trials in which systemic
administrations of AAV2/8 vectors are used. Therefore, we
screened MPS VI patients for Nab to AAV8, which were
undetectable in 58% of subjects. Among the MPS VI pa-
tients tested for Nab to AAV8, the titer was > 1:20 in 15%
and > 1:80 in 12% of subjects. These results are consistent
with previously published data showing that the ser-
oprevalence of Nab to AAV8 at serum dilution of > 1:20
and > 1:80 is about 20% and 15%, respectively, in samples
from healthy European individuals.22,31 The seroprevalence
of Nab to AAV8 observed in our cohort is slightly lower
than that (33%) reported in both healthy subjects and he-
mophilic patients from Japan.32
No definitive conclusions can be drawn from the analyses
of AAV8 seroprevalence stratified by referral centers, age,
or clinical severity because of the small sample size.
However, we have observed that AAV8 seroprevalence
varies between samples collected from different referral
centers and is highest in patients of Asiatic origin (50%)
followed by patients of European and African origins (33%
each). These observations support previous studies in which
AAV seroprevalence was shown to vary depending on the
geographical origin of the studied population; this was
probably at least partially attributed to living conditions or
population density.22,33 In line with a previous study
showing that seroprevalence to AAV8 significantly in-
creases through the childhood and the adolescence in
healthy subjects,34 the seroprevalence to AAV8 we have
measured is higher in adolescents than in children and does
not correlate with the clinical severity of the disease (Fisher
exact test p-value = 0.95; power 0.06), which may account
for an increased exposure because of more frequent clinic or
hospital admissions.
Gene therapy efficacy may be additionally limited by T-
cell-mediated and humoral immunity to the therapeutic
transgene product. T-cell-mediated responses to rhARSB
have not been reported in MPS VI patients treated with
ERT.2,35 On the other hand, recent results from phase I/II
liver gene therapy clinical trials for hemophilia B and acute
intermittent porphyria showed no T-cell-mediated immune
responses to the therapeutic transgene product,15,36 sug-
gesting that this might not be a major limitation for liver
gene therapy.
The risk of humoral immunity to the transgene product
correlates with the presence of CRIM.9,13 Here, we show
that the CRIM positivity of MPS VI patients could be pre-
cisely predicted by the presence of at least one ARSB allele
carrying a missense mutation. To the best of our knowledge,
this is the first example of analysis, which correlates the
genotype of MPS VI patients with ARSB CRIM, clearly
showing that the CRIM status could be predicted based on
ARSB mutations. On the contrary, there was no correlation
between CRIM status and disease severity. The frequencies
of ARSB missense and null mutations that we found in our
series of MPS VI patients (62.5% and 37.5%, respectively)
are similar to those previously found in a larger patient
cohort.37
While even low levels of Nab to AAV8 should be viewed
as an exclusion criterion for a trial with AAV2/8 infusions,
exclusion of ARSB CRIM-negative MPS VI patients is
debatable. First, almost all MPS VI patients treated with
ERT develop antibodies to rhARSB independently of their
genotypes or disease severity.4,23,38–40 Nevertheless, they
experience clinical benefits under ERT.4,38–40 In addition,
liver-directed gene therapy has been demonstrated to either
prevent the generation of humoral immunity18 or to eradi-
cate it, if already present,19,20 which makes the impact of
preexisting humoral immunity to the transgene product on
gene therapy efficacy difficult to predict. Therefore, there is
a good argument for not excluding neither patients with
preexisting immunity to rhARSB nor ARSB CRIM-negative
patients from the trial.
Although CRIM-negative status would not be an exclu-
sion criterion, CRIM-positive patients may be preferred in a
gene therapy trial as they have lower possibility to generate
humoral immunity to the newly synthesized transgene
product secreted by transduced hepatocytes.9,13 The current
study has revealed that 12 of 19 patients negative for Nab to
AAV8 were also CRIM positive. These 12 patients corre-
spond to 39% of the patients analyzed for both markers.
Although using both criteria will likely result in a significant
reduction of eligible MPS VI subjects, based on the esti-
mated number from this study, a phase I/II, open-label,
dose-escalation (2 patients treated at a low, 3 at an inter-
mediate, and 3 at a high dose of vector) safety study would
still be feasible.
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